Toll Like Receptor 3 (CD283 or TLR3) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Toll Like Receptor 3 (CD283 or TLR3) – Pipeline Review, H2 2016’, provides in depth analysis on Toll Like Receptor 3 (CD283 or TLR3) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)

The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Biomics Biotechnologies Co., Ltd.

Hemispherx Biopharma, Inc.

Idera Pharmaceuticals, Inc.

Innate Pharma S.A.

Johnson & Johnson

MultiCell Technologies, Inc.

Oncovir, Inc.

Tollys S.A.S

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Toll Like Receptor 3 (CD283 or TLR3) Overview 7

Therapeutics Development 8

Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Stage of Development 8

Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Therapy Area 9

Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Indication 10

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Companies 14

Toll Like Receptor 3 (CD283 or TLR3) - Products under Development by Universities/Institutes 17

Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development 26

Biomics Biotechnologies Co., Ltd. 26

Hemispherx Biopharma, Inc. 27

Idera Pharmaceuticals, Inc. 28

Innate Pharma S.A. 29

Johnson & Johnson 30

MultiCell Technologies, Inc. 31

Oncovir, Inc. 32

Tollys S.A.S 33

Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles 34

Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Antisense RNAi Oligonucleotide to Agonize TLR-3 for Age Related Macular Degeneration - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CNTO-3157 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Drugs to Activate TLR3 for Atherosclerosis - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

IPH-33 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

MCT-465 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Oligonucleotide to Agonize TLR3 for Oncology - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Oligonucleotides to Agonize TLR3 for Infectious Disease and Immunology - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

P-7 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Poly-ICLC - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

rabies vaccine - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

rintatolimod - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecule to Antagonize TLR-3 for Gastrointestinal Syndrome - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Small Molecules to Antagonize TLR-3 for Infectious Disease and Immunology - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Stathmin-1 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Toll Like Receptor 3 (CD283 or TLR3) - Dormant Projects 60

Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products 63

Toll Like Receptor 3 (CD283 or TLR3) - Featured News & Press Releases 64

Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology 64

Jun 06, 2016: Hemispherx Biopharma Obtains a Comprehensive Carter Omnibus Assignment of Intellectual Property 65

Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke 65

Feb 09, 2016: Hemispherx Biopharma Exploring Possible Research Program in Zika Virus Using Ampligen 66

Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant 66

Sep 28, 2015: Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen Formulations 68

Sep 23, 2015: Hemispherx Biopharma Reports Article by Senior Authors from Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen to Multiple Sclerosis 69

Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen 70

Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study 71

Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms 72

Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe 72

Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division’s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations 73

May 26, 2015: Hemispherx Biopharma Europe : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease 74

May 11, 2015: Hemispherx Biopharma Europe Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD) 74

Mar 24, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD) 75

Appendix 77

Methodology 77

Coverage 77

Secondary Research 77

Primary Research 77

Expert Panel Validation 77

Contact Us 77

Disclaimer 78

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016 26

Pipeline by Hemispherx Biopharma, Inc., H2 2016 27

Pipeline by Idera Pharmaceuticals, Inc., H2 2016 28

Pipeline by Innate Pharma S.A., H2 2016 29

Pipeline by Johnson & Johnson, H2 2016 30

Pipeline by MultiCell Technologies, Inc., H2 2016 31

Pipeline by Oncovir, Inc., H2 2016 32

Pipeline by Tollys S.A.S, H2 2016 33

Dormant Projects, H2 2016 60

Dormant Projects (Contd..1), H2 2016 61

Dormant Projects (Contd..2), H2 2016 62

Discontinued Products, H2 2016 63

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports